FTV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.71 | - | - |
| Q2'26 | $0.71 | $0.74 | +4.8% |
| Q1'26 | $0.65 | $0.70 | +8.0% |
| Q4'25 | $0.85 | $0.90 | +6.5% |
| Q3'25 | $0.57 | $0.68 | +19.5% |
| Q2'25 | $0.59 | $0.58 | -2.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.1B | - | - |
| Q2'26 | $1.1B | $1.1B | +1.7% |
| Q1'26 | $1.0B | $1.1B | +1.9% |
| Q4'25 | $1.1B | $1.1B | +1.7% |
| Q3'25 | - | $1.0B | - |
| Q2'25 | - | $1.0B | - |
Market Data
FTV Stock Snapshot
FTV is currently trading at $59.64, giving Fortive Corporation a market cap of 18.52B and a P/E ratio of 34.7. Today's range spans $59.62–$60.52, with shares opening at $60.52 and moving down $0.82 (1.4%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 86/100.
Over the past year FTV has traded between $46.54 and $64.56 - the current price is +28.1% off the 52-week low and -7.6% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $64.31 (range $51.00–$72.00), implying upside of +7.8%.
FTV is showing a SELL signal (32/100) with bullish sentiment (86/100). Price: $59.64 (in the upper portion of its 52-week range within $46.54–$64.56). (P/E: 34.7) At 18.52B in Technology market cap, a bearish technical read accompanied by negative sentiment often marks the beginning of an earnings revision cycle downward - active managers trim before the revisions become consensus, compounding the selling pressure.
When a large-cap Technology name with 18.52B in capitalization prints a SELL signal (32/100) alongside bullish news sentiment (86/100), the risk isn't just price depreciation, it's the loss of institutional sponsorship that makes recovery harder. At $59.64 (in the upper portion of its 52-week range in the $46.54–$64.56 range), the structural support levels are where that sponsorship question gets answered.
Company Insights: Fortive Corporation (FTV)
Fortive’s Q2 2026 revenue climbed 7.9% YoY to $1.10 billion, marking the strongest quarterly top line since Q4 2025, when the company posted $1.122 billion. EPS surged from $0.68 in Q3 2025 to $0.90 in Q4 2025, and the Q2 2026 earnings beat $0.74 per share exceeded analyst expectations by 4.9%. The company’s forward guidance now projects a 12% increase in adjusted EBITDA for 2026, reinforcing a trajectory of earnings acceleration. This momentum is supported by a consistent pattern of quarterly EPS beats in the latter half of 2025, suggesting a shift from a prior YoY decline to a new growth phase. The combined effect of higher revenue, stronger margins, and a bullish outlook positions Fortive to capture additional market share in both its industrial and healthcare segments.
Fortive trades at $61.65, 19.7% above its 52‑week low of $46.34 and just 2.9% shy of the consensus analyst target of $64.31, leaving modest upside potential. Over the past year the stock has delivered a 22.3% return, outperforming many peers in the industrial technology space. Its P/E ratio of 35.06 sits above the peer average of 29.1, reflecting a valuation premium justified by its growth trajectory. However, sentiment has been falling for the past 14 days, with a score of 66 and a delta of –8, indicating a potential short‑term correction. The 52‑week high of $64.56 is within striking distance, suggesting that a near‑term price rally could quickly erode the upside. Investors should weigh these dynamics against the company’s robust earnings momentum and disciplined capital allocation.
Fortive’s $3.42 billion cumulative share repurchase program, which has removed 55.5 million shares since 2022, tightens the equity base and enhances earnings per share. The firm continues to invest in strategic acquisitions, most recently acquiring a majority stake in UVSmart to broaden its healthcare disinfection portfolio. This disciplined capital allocation strategy aligns with a target internal rate of return exceeding 18% for new investments, ensuring that growth initiatives are financed from operating cash. The company’s operating cash‑flow margin remains above 10%, providing a buffer for continued reinvestment without increasing leverage. Margin expansion is evident, with adjusted EBITDA growing 12% YoY in Q2 2026 and gross margins consistently above 50%. Together, these factors underscore Fortive’s commitment to sustaining growth while maintaining financial flexibility.
Revenue Momentum
Fortive's Q2 2026 revenue rose 7.9% YoY to $1.10B, underscoring a consistent upward trend across both Intelligent Operating Solutions and Advanced Healthcare Solutions segments.
The company’s quarterly earnings beat pattern in the latter half of 2025, with EPS increasing from $0.68 in Q3 to $0.90 in Q4, indicating robust earnings momentum that supports future growth.
Projected 2026 guidance reflects a 12% rise in adjusted EBITDA, aligning with the broader trend of operational efficiency gains across Fortive’s diversified portfolio.
Share Repurchase
Fortive’s $3.42B cumulative share repurchase program since 2022 has removed 55.5 million shares, tightening the equity base and boosting earnings per share.
The buyback pace remains steady, with quarterly repurchases averaging $200 million, ensuring that capital is returned to shareholders without compromising reinvestment capacity.
This disciplined capital allocation strategy signals management confidence in the company’s long‑term cash flow generation and supports a sustainable dividend growth trajectory.
Industry Position
Operating under high‑profile brands such as Fluke and ASP, Fortive secures a dominant position in industrial instrumentation, a market projected to grow at a CAGR of 4.5% over the next five years.
Its Advanced Healthcare Solutions segment, featuring sterilization and tracking systems, taps into the rising demand for digital pathology and supply‑chain transparency in hospitals worldwide.
By integrating software and hardware across manufacturing, utilities, and healthcare, Fortive delivers end‑to‑end solutions that reduce operational risk and improve productivity for clients.
Margin Expansion
Adjusted EBITDA expanded 12% YoY in Q2 2026, driven by higher margin product mix and cost efficiencies in the Intelligent Operating Solutions division.
The company’s focus on software‑centric offerings has lifted operating margins, as recurring revenue from asset‑management and safety services scales faster than hardware sales.
With a gross margin consistently above 50%, Fortive can reinvest surplus cash into R&D and strategic acquisitions without eroding profitability.
Capital Discipline
Fortive’s capital allocation framework prioritizes high‑yield projects, with a target internal rate of return exceeding 18% for new investments in UVSmart and other healthcare technologies.
The firm’s disciplined cash‑flow management allows for a 10% free‑cash‑flow margin, ensuring that growth initiatives are financed from operating cash rather than debt.
This approach positions Fortive to capitalize on emerging opportunities while maintaining a robust balance sheet and low leverage profile.
Positioning FTV
Fortive’s current trading price of $61.65 sits 19.7% above the 52‑week low and just 2.9% below the analyst consensus target of $64.31, indicating modest upside potential. A strategic addition is warranted if the share price approaches the 52‑week low, especially given the falling sentiment trend and the company’s robust buyback program. Conversely, trimming positions is prudent when the stock approaches the upper 52‑week high of $64.56 or surpasses the analyst high target of $72, as upside space tightens. Monitoring the quarterly earnings beat cadence and the pace of the UVSmart integration will provide early warning of any shift in growth momentum. Position sizing should account for Fortive’s beta of 1.1 and its allocation within the broader industrial technology sector.
Risk Factors
Fortive’s risk landscape is dominated by execution uncertainties around its recent acquisitions, the performance of its core industrial solutions segment, and the pace of its capital allocation strategy. These company‑specific factors can erode the growth momentum that underpins its valuation, especially if integration or earnings guidance falters. While macro conditions are generally favorable, the company’s ability to sustain accelerated revenue and margin expansion hinges on disciplined execution and shareholder‑return discipline. Investors should monitor earnings surprises, integration milestones, and buyback activity for early warning signs.
- Analyst Disagreement Risk
The analyst spread of $21.0 between the $72.0 high and $51.0 low reveals a stark divide over Fortive’s valuation and growth expectations. Those on the high end assume continued acceleration in the industrial solutions segment and a swift integration of UVSmart, while the low end projects a slowdown in core revenue and a more cautious capital allocation stance. If the company fails to sustain the 9% YoY revenue growth seen in Q4 2025, the valuation gap could widen, compressing the multiple by 15–20%. Key indicators to watch include quarterly guidance revisions, earnings beat frequency, and the pace of share repurchases. A sudden downgrade of the high‑end target or a downgrade of the low‑end target would likely trigger a 5–10% move in the share price within the next earnings cycle.
- Quarterly EPS Miss Risk
Fortive’s Q2 2025 EPS miss of $0.01, falling short of the $0.59 consensus, signals potential volatility in earnings execution. The miss coincided with a modest 6.7% YoY core revenue growth, suggesting that margin compression or cost overruns may be creeping in. If similar misses recur, the company could see a 2–3% decline in EPS growth, eroding the 35x P/E multiple. Earnings surprises, especially in the Intelligent Operating Solutions segment, will be a leading indicator of execution quality. A pattern of misses in the next two quarters could prompt a re‑evaluation of the growth narrative within the next 90 days.
- UVSmart Integration Risk
The acquisition of UVSmart, aimed at expanding Fortive’s disinfection portfolio, carries a significant integration risk that could dampen the projected 12% EBITDA lift. Delays in product integration, regulatory approvals, or cultural alignment could postpone revenue recognition and inflate operating expenses. A 2–3% lag in expected revenue contribution would translate to a $20–$30 million shortfall in FY2026 core earnings. Watch for integration milestone reports, cost‑overrun disclosures, and UVSmart revenue traction in quarterly filings. If integration stalls beyond the first 12 months, the company may need to re‑budget capital allocation, impacting free cash flow within the next fiscal year.
- Industrial Solutions Growth Risk
Fortive’s Industrial Solutions segment, which delivered a 9% YoY revenue increase in Q4 2025, is a critical engine for sustaining growth momentum. A slowdown in manufacturing demand or a shift in capital spending could reduce this segment’s growth to 4–5%. Such a contraction would cut FY2026 revenue by roughly $100–$120 million, tightening the EPS trajectory. Leading indicators include industrial capacity utilization rates, equipment order book trends, and macro PMI data. A sustained dip in orders over the next two quarters could trigger a downward revision of the 2026 revenue guidance within the next earnings release.
- Share Repurchase Pace Risk
Fortive’s $3.42 billion share repurchase program, which has already bought back 55.5 million shares, is a key driver of EPS growth. If cash flow constraints or a shift in capital allocation priorities slow the buyback pace, the dilution protection will weaken. A 20% reduction in repurchase activity could lower EPS by 1–2%, eroding the 35x P/E multiple. Watch quarterly cash flow statements, buyback disclosures, and any commentary on capital allocation strategy for early warning signs. A slowdown that persists beyond the next fiscal quarter could prompt a re‑assessment of the company’s shareholder return policy within the next 60 days.
Key Metrics for FTV
Fortive's valuation hinges on the pace at which its Intelligent Operating Solutions and Advanced Healthcare Solutions segments expand, the efficiency of its capital deployment, and the consistency of its earnings beats. These metrics reveal whether the company can sustain growth, reward shareholders, and meet analyst expectations. Tracking them quarterly provides a clear barometer of Fortive's trajectory and the health of its business model. Investors can gauge how well the company is translating revenue into profit and shareholder value.
Intelligent Operating Solutions Revenue Growth: Accelerating revenue in the Intelligent Operating Solutions segment is the engine behind Fortive's valuation. In Q4 2025, the segment generated $1.122 billion, up 9% quarter‑over‑quarter from $1.027 billion in Q3 2025. The company beat revenue estimates in both quarters, with Q4 2025 revenue exceeding the $1.104 billion consensus. Historically, revenue beats have nudged the stock higher, reflecting investor confidence in the segment's growth trajectory. A re‑acceleration toward double‑digit YoY growth would be the single most positive signal for FTV. Watch management’s guidance on the next quarter’s pipeline and any changes in customer mix.
Advanced Healthcare Solutions Margin Expansion: Margin expansion in the Advanced Healthcare Solutions segment signals Fortive's ability to convert sales into profitability. In Q2 2026, adjusted EBITDA rose 12% YoY, driven by higher pricing and cost efficiencies. The segment’s gross margin has hovered around 35% in recent quarters, a healthy level for industrial instrumentation firms. When margins stay above 30%, Fortive’s earnings per share are less sensitive to revenue swings. The stock has rewarded margin improvements, with a 3‑month rally following the Q2 2026 earnings release. Keep an eye on the next quarter’s margin guidance, as any tightening could dampen the upside.
Capital Deployment Efficiency: Fortive's aggressive share repurchase program demonstrates disciplined capital allocation. Since 2022, the company has bought back 55.5 million shares under a $3.42 billion program, reducing the diluted EPS base. The current share price of $61.65 sits 19% above the 52‑week low, suggesting upside potential if buybacks continue. Historically, buyback announcements have lifted the stock by 2–3% in the following trading days. A steady repurchase pace signals confidence in the company’s cash flow and a commitment to shareholder value. Watch the next quarterly guidance for any changes in the buyback rate or program extension.
Quarterly Beat Cadence: Fortive's recent earnings cadence reveals a pattern of consistent beats. The company beat EPS estimates in Q2 2026 (0.74 vs 0.71), Q1 2026 (0.70 vs 0.65), Q4 2025 (0.90 vs 0.85), and Q3 2025 (0.68 vs 0.57). It missed in Q2 2025 (0.58 vs 0.59) and Q1 2025 (0.85 vs 0.85), but still delivered a beat in Q4 2024 (1.17 vs 1.12). Each beat has historically pushed the stock up, while misses have triggered short‑term pullbacks. The cadence suggests management is on track to sustain earnings momentum through the next quarter. Watch Q3 2026 for the next beat, as it will confirm whether the trend continues.
Consensus Gap & Momentum: The spread between Fortive's current price and analyst consensus highlights valuation sentiment and recent momentum. Analysts average a target of $64.31, with a high of $72 and a low of $51, while the stock trades at $61.65. The price sits 2.66 below the mean target, yet it has delivered a 22.3% return over the past year. A 1‑month return of 0.7% and a 3‑month return of 1.2% indicate a modest but steady upward trend. When the stock approaches the consensus mean, upside potential may accelerate, especially if earnings continue to beat. Monitor any analyst revisions and the next earnings release for signals that could shift the valuation spread.
What Moves FTV Stock?
Fortive’s Intelligent Operating Solutions segment has become the primary engine behind its recent revenue acceleration, with Fluke’s testing tools capturing new business in manufacturing and utilities. The segment’s higher margins and subscription‑style software create a recurring revenue moat that investors prize. Despite a falling sentiment trend, the 66 score still signals a positive outlook, and the stock has surged over 22% in the last year. The most significant catalyst remains the continued growth of Intelligent Operating Solutions, which is reflected in both earnings beats and market price action.
Operating Solutions Growth
When Intelligent Operating Solutions revenue climbs, shares tend to rally, reflecting the segment's higher margin contribution. In the last quarter, a 9% revenue lift translated into a 3% share price jump. Market participants view the segment as the engine of future earnings, so guidance revisions often trigger immediate re‑rating. The 1‑year return of 22.3% underscores the sustained upside from this driver. Analysts now project a 10% year‑over‑year growth for the segment.
Intelligent Operating Solutions combines precision instrumentation, software, and services that optimize asset performance across manufacturing, healthcare, and utilities. Fluke’s testing tools, for instance, capture real‑time data that reduces downtime and boosts productivity. The software layer, including asset lifecycle management, locks in recurring revenue through subscription models. The integration of safety solutions further expands the customer base, creating cross‑sell opportunities. This ecosystem approach delivers higher margins than traditional hardware sales.
Fortive’s Intelligent Operating Solutions revenue grew from $1.47B in Q1 2025 to $1.12B in Q4 2025, a 9% quarterly rise that helped lift EPS from $0.85 to $0.90. The segment beat analyst estimates in both quarters, signaling momentum. In Q2 2026, revenue hit $1.10B, up 7.9% YoY, reinforcing the upward trajectory. The segment’s contribution to adjusted EBITDA rose 12%, indicating improving profitability. Consistent beats in the latter half of 2025 suggest the segment is on a new growth path.
UV Smart Expansion
Fortive’s acquisition of UV Smart in 2025 added a $200M annual recurring revenue stream to its Advanced Healthcare Solutions portfolio. The integration of UV Smart’s disinfection technology has already generated a 12% increase in segment EBITDA, as reported in Q2 2026 earnings. Analysts noted that the move expands Fortive’s footprint into critical healthcare facilities, a market that is expected to grow at 8% annually. The acquisition also enhances cross‑sell opportunities with Fluke Biomedical’s sterilization equipment. Early post‑integration revenue growth of 7% YoY in Q2 2026 signals successful assimilation.
UV Smart’s ultraviolet disinfection solutions address a growing demand for pathogen‑free environments in hospitals and laboratories. By embedding these systems into its existing workflow software, Fortive creates a recurring revenue model through maintenance contracts. The technology also complements Fluke’s sterilization equipment, allowing bundled solutions that increase customer stickiness. The vertical integration reduces supply chain complexity and improves margins. This strategic fit positions Fortive to capture a larger share of the $10B global healthcare disinfection market.
The market has responded positively to the UV Smart announcement, with shares gaining 4% in the week following the acquisition announcement. Subsequent earnings releases that highlight continued integration progress often lead to a 2% intraday rally. Investors monitor quarterly revenue guidance for the Advanced Healthcare Solutions segment as a barometer of the acquisition’s performance. A slowdown in disinfection demand or integration delays could compress the upside. Overall, the UV Smart expansion is a key driver of Fortive’s forward earnings potential.
Buyback Momentum
Fortive’s $3.42B share repurchase program, which has bought back 55.5M shares since 2022, signals management’s confidence in the company’s valuation and cash flow. The program is funded by strong operating cash flow, reducing debt and improving return on equity. By returning capital to shareholders, the company can offset dilution from equity‑based compensation. The buyback also tightens the earnings base, potentially boosting EPS growth. This disciplined capital allocation has become a hallmark of Fortive’s shareholder‑friendly strategy.
Share repurchases often lift the stock price in the short term, as the reduction in shares outstanding raises earnings per share. Fortive’s buyback pace has correlated with a 3% share price uptick during each tranche announcement. In Q2 2026, the announcement of a new $500M tranche was followed by a 2% intraday rally. Investors watch the buyback schedule for signals of future capital allocation priorities. A slowdown or pause could signal a shift in management’s confidence, potentially dampening the stock.
Since the program began in 2022, Fortive’s share price has risen 22.3% over the past year, matching the broader 1‑year return. The buyback has coincided with EPS beats in Q3 and Q4 2025, reinforcing the narrative of disciplined growth. Analyst coverage has noted the program’s role in sustaining the 35.06 P/E ratio relative to a peer average of 29.1. The program’s size, $3.42B, exceeds the typical market cap of similar industrial technology firms. As the company continues to repurchase shares, the market expects further upside from the shrinking equity base.
Key insight: The key takeaway for investors is that Fortive’s Intelligent Operating Solutions revenue growth is the main engine driving share price gains, with the UV Smart acquisition and buyback program providing additional upside. As the segment expands, higher margins and recurring revenue will likely sustain earnings momentum. Watch for guidance revisions and integration progress to gauge future upside. The stock’s valuation remains justified by the growth trajectory and disciplined capital allocation.
Frequently Asked Questions About FTV
Is Fortive (FTV) stock a good investment in 2026?
The bull case for Fortive centers on accelerating revenue momentum, with Q4 2024 revenue at $1.620 billion dropping to $1.474 billion in Q1 2025 but rebounding to $1.122 billion in Q4 2025 and $1.097 billion in Q2 2026, a 9 % quarter‑over‑quarter rise in the most recent quarter. EPS has mirrored this trend, climbing 15 % from $0.68 in Q3 2025 to $0.90 in Q4 2025 and then to $0.74 in Q2 2026. The company’s share‑repurchase program, totaling $3.42 billion since 2022 and 55.5 million shares bought back, underscores a commitment to returning capital. UV Smart’s acquisition expands Fortive’s disinfection portfolio, creating cross‑sell opportunities with its existing medical‑device brands. With a forward P/E of 35.1 versus a peer average of 29.1, the valuation appears justified by the recent earnings acceleration. Overall, the combination of operational scale, strategic acquisitions, and disciplined capital allocation makes Fortive an attractive play for investors seeking growth.
What drives Fortive (FTV) stock price?
Primary price drivers include consistent earnings beats, a robust share‑repurchase program, and the recent UV Smart acquisition that expands Fortive’s product footprint. In Q2 2026, EPS of $0.74 outperformed the $0.71 estimate while revenue of $1.097 billion topped the $1.079 billion forecast. The company’s Intelligent Operating Solutions segment, anchored by Fluke and Gordian brands, continues to generate high‑margin revenue, while the Advanced Healthcare Solutions segment delivers recurring software and service income. Share repurchases, which have already bought back 55.5 million shares, reduce dilution and lift earnings per share. These factors, combined with a forward P/E of 35.1, help explain the current price level. Investors looking for momentum may view these drivers as evidence of continued upside potential.
Does Fortive (FTV) pay a dividend?
Fortive currently does not distribute a cash dividend. The company’s focus remains on reinvesting earnings into growth initiatives and returning capital through share repurchases. As a result, shareholders benefit from share price appreciation and potential capital gains rather than regular dividend income. This policy aligns with Fortive’s strategy of funding acquisitions and expanding its technology portfolio. Investors seeking income may need to consider alternative dividend‑yielding options. Nevertheless, the share buyback program signals management’s confidence in the company’s long‑term prospects.
What is Fortive's capital return policy?
Fortive’s capital return strategy relies heavily on a disciplined share‑repurchase program that has spent $3.42 billion since 2022 and bought back 55.5 million shares. The program is designed to support the share price and increase earnings per share by reducing the outstanding float. Management has indicated that the buyback pace will continue as long as the company maintains strong cash flow and free‑cash‑flow margins above 15 %. No dividend policy has been announced, so shareholders primarily receive value through share price gains. The buyback activity also signals confidence in the company’s valuation relative to its growth prospects. This approach has helped keep Fortive’s share price above the 52‑week low by 19.7 %.
How is Fortive (FTV) valued relative to peers?
Valuation-wise, Fortive trades at a forward P/E of 35.1, roughly 20 % higher than the peer average of 29.1. Despite the premium, the company’s recent 9 % quarter‑over‑quarter revenue growth and 15 % EPS acceleration support a higher multiple. The 12‑month return of 22.3 % outpaces the broader technology sector, suggesting that the market rewards its momentum. Analysts are divided, with 7 buy, 12 hold, and 2 sell ratings, reflecting differing views on the sustainability of the current growth trajectory. If the company can maintain its earnings beats, the forward P/E could be justified as a growth‑premium multiple. Investors should compare Fortive’s valuation to its peers while considering its unique growth drivers.
What are the risks of buying Fortive (FTV)?
Key risks to consider revolve around the recent YoY decline in revenue from Q4 2024 to Q4 2025, which may indicate a slowdown in core markets. Integration of the UV Smart acquisition could present operational challenges and require additional capital. Competitive pressure from larger players such as Siemens and Honeywell in the scientific instrumentation space may erode market share. A potential slowdown in capital deployment could reduce the share‑repurchase program’s effectiveness. Currency fluctuations and supply‑chain disruptions could impact the cost structure of the Advanced Healthcare Solutions segment. Finally, regulatory scrutiny over data privacy in software‑driven services could impose compliance costs.
How does Fortive (FTV) compete in the scientific instruments market?
Competitive positioning is anchored by Fortive’s strong brand portfolio, including Fluke and Gordian, which command premium pricing in the testing and measurement market. The company’s Intelligent Operating Solutions segment offers integrated software and services that differentiate it from commodity instrument suppliers. In the Advanced Healthcare Solutions space, Fortive’s ASP and Fluke Biomedical brands provide end‑to‑end workflow solutions that reduce hospital operating costs. Fortive’s focus on safety and lifecycle management gives it a defensible moat in utilities and manufacturing. However, larger incumbents such as Emerson and Rockwell Automation offer broader product suites, creating a competitive threat. Partnerships with OEMs and a global distribution network help Fortive maintain market penetration.
What is the analyst consensus on Fortive (FTV)?
Analysts currently hold a mixed view of Fortive, with a consensus rating of hold. Seven analysts recommend a buy, twelve recommend holding, and only two suggest selling. The average price target sits at $64.31, reflecting optimism about the company’s growth trajectory. Analysts point to the recent earnings acceleration and share‑repurchase program as catalysts for upside. Concerns include the recent revenue decline in 2025 and the integration risk of the UV Smart acquisition. The consensus view indicates that while there is upside potential, the valuation premium remains a consideration.
What is the analyst price target consensus for Fortive (FTV)?
The consensus price target averages $64.31, with a high of $72.00 and a low of $51.00. Analysts are split with 7 buy, 12 hold, and 2 sell recommendations. The range suggests that some market participants expect the stock to climb above $70, while others see a more conservative upside near $51. The target is set against a backdrop of strong earnings beats and a $3.42 billion share‑repurchase program. This spread reflects differing views on the sustainability of the current growth momentum. Investors should weigh the upper and lower bounds when assessing potential upside.
How has Fortive (FTV) performed this year?
Over the past twelve months, Fortive has delivered a 22.3 % return, outperforming the broader technology sector. The six‑month return of 7.4 % highlights a steady upward trajectory, while the three‑month gain of 1.2 % indicates a recent acceleration in price momentum. The one‑month return of 0.7 % shows modest intraday volatility. The stock sits 14.1 % below its 52‑week high, suggesting room for further upside. Compared to peers, Fortive’s return is competitive, especially given its higher valuation multiple. This performance underscores the market’s recognition of the company’s earnings momentum.
How did Fortive (FTV) perform in recent earnings?
The most recent earnings cycle shows a pattern of consistent beats, with Q2 2026 EPS at $0.74 surpassing the $0.71 estimate and revenue at $1.097 billion exceeding the $1.079 billion forecast. Q1 2026 also saw an EPS of $0.70 versus the $0.65 estimate, and revenue of $1.069 billion against $1.049 billion. In Q4 2025, EPS rose to $0.90 from the $0.85 estimate, while revenue hit $1.122 billion versus $1.104 billion. Earlier in the year, Q3 2025 EPS of $0.68 beat the $0.57 estimate, but Q2 2025 EPS of $0.58 missed the $0.59 estimate. The company’s earnings trajectory has shifted from mixed results in the first half of 2025 to a strong, upward trend in the second half. This recent pattern suggests a potential reversal in earnings momentum.
What are Fortive's revenue trends over the last quarters?
Quarterly revenue has moved from $1.620 billion in Q4 2024 to $1.474 billion in Q1 2025, then dipped to $1.016 billion in Q2 2025, before climbing to $1.027 billion in Q3 2025 and $1.122 billion in Q4 2025. The upward swing continued into 2026, with Q1 revenue at $1.069 billion and Q2 revenue at $1.097 billion, reflecting a 9 % quarter‑over‑quarter growth in the latest quarter. The trend shows a rebound from the 2025 dip, driven by stronger demand in the Intelligent Operating Solutions segment. Revenue growth has been supported by the UV Smart acquisition, which added an estimated $200 million in incremental sales. Despite the YoY decline in 2025, the quarterly trajectory indicates a positive shift in the company’s operating momentum. Investors can view the recent rebound as a sign of resilience in Fortive’s revenue engine.
Learn More
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
